Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out

An announcement from Pharvaris ( (PHVS) ) is now available.

On May 8, 2026, Pharvaris N.V. signed an underwriting agreement with a syndicate led by Morgan Stanley and Leerink Partners to issue and sell 4,455,863 ordinary shares, including the full exercise of the underwriters’ option, in an underwritten public offering that closed on May 11, 2026. The shares were priced at $29.68, generating expected net proceeds of about $124 million, which the company plans to deploy mainly on late-stage R&D, building a U.S. sales and marketing team and commercialization capabilities, as well as general corporate and working-capital needs, underscoring its transition from a clinical-stage developer toward a more commercially focused biopharma player.

The equity raise strengthens Pharvaris’s balance sheet ahead of pivotal development and potential launch activities, signaling confidence from capital markets in its clinical pipeline and commercialization strategy. By funding both research and commercial infrastructure, the transaction may accelerate time to market for its lead programs and could dilute existing shareholders in the near term while positioning the company more competitively in the rare disease therapeutics landscape.

The most recent analyst rating on (PHVS) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.

Spark’s Take on PHVS Stock

According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.

The score is primarily held back by weak financial performance driven by ongoing losses and increasing cash burn, despite a conservatively levered balance sheet. Technicals are supportive with the stock trading above major moving averages and positive momentum, while valuation remains challenged due to a negative P/E and no dividend yield provided.

To see Spark’s full report on PHVS stock, click here.

More about Pharvaris

Pharvaris N.V. is a Netherlands-based biopharmaceutical company focused on developing oral therapies, including late-stage clinical programs, for hereditary angioedema and related conditions. The company is building a U.S.-oriented commercial infrastructure, including a sales and marketing team, to support future product launches in rare disease markets.

Average Trading Volume: 223,999

Technical Sentiment Signal: Buy

Current Market Cap: $1.93B

Find detailed analytics on PHVS stock on TipRanks’ Stock Analysis page.